Abstract: At present, there is a lack of effective treatment methods for acquired reactive perforating collagenosis. Tofacitinib, an oral pan-JAK inhibitor, can effectively inhibit the activity of JAK1 and JAK3 and block the signal transduction of a variety of inflammatory cytokines, thus playing a role in the intervention of inflammatory diseases. Herein, we report a patient with acquired reactive perforating collagenosis successfully treated with tofacitinib and review the relevant literature. A 24-year-old man presented with itchy papules and nodules on his head, neck, shoulders, and back. The skin rash disappeared after treated with tofacitinib for 2 months and no recurrence was observed during one-year follow-up.

Key words: tofacitinib, acquired reactive perforating collagenosis, JAK inhibitor